Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients
- PMID: 16274485
- PMCID: PMC1308867
- DOI: 10.1186/1465-9921-6-133
Sequential analysis of surfactant, lung function and inflammation in cystic fibrosis patients
Abstract
Background: In a cross-sectional analysis of cystic fibrosis (CF) patients with mild lung disease, reduced surfactant activity was correlated to increased neutrophilic airway inflammation, but not to lung function. So far, longitudinal measurements of surfactant function in CF patients are lacking and it remains unclear how these alterations relate to the progression of airway inflammation as well as decline in pulmonary function over time.
Methods: As part of the BEAT trial, a longitudinal study to assess the course of airway inflammation in CF, we studied lung function, surfactant function and endobronchial inflammation using bronchoalveolar lavage fluid from 20 CF patients with normal pulmonary function (median FEV1 94% of predicted) at three times over a three year period.
Results: There was a progressive loss of surfactant function, assessed as minimal surface tension. The decline in surfactant function was negatively correlated to an increase in neutrophilic inflammation and a decrease in lung function, assessed by FEV1, MEF(75/25%VC), and MEF(25%VC). The concentrations of the surfactant specific proteins A, C and D did not change, whereas SP-B increased during this time period.
Conclusion: Our findings suggest a link between loss of surfactant function driven by progressive airway inflammation and loss of small airway function in CF patients with limited lung disease.
Figures





Similar articles
-
Pulmonary surfactant, lung function, and endobronchial inflammation in cystic fibrosis.Am J Respir Crit Care Med. 2004 Nov 1;170(9):1000-5. doi: 10.1164/rccm.200405-575OC. Epub 2004 Jul 21. Am J Respir Crit Care Med. 2004. PMID: 15271694
-
Pulmonary surfactant dysfunction in pediatric cystic fibrosis: Mechanisms and reversal with a lipid-sequestering drug.J Cyst Fibros. 2017 Sep;16(5):565-572. doi: 10.1016/j.jcf.2017.04.015. Epub 2017 Jun 7. J Cyst Fibros. 2017. PMID: 28599957
-
Lung surfactant in a cystic fibrosis animal model: increased alveolar phospholipid pool size without altered composition and surface tension function in cftrm1HGU/m1HGU mice.Thorax. 1997 Aug;52(8):723-30. doi: 10.1136/thx.52.8.723. Thorax. 1997. PMID: 9337833 Free PMC article.
-
Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.Paediatr Drugs. 2005;7(6):353-63. doi: 10.2165/00148581-200507060-00004. Paediatr Drugs. 2005. PMID: 16356023 Review.
-
Cystic Fibrosis Lung Disease: An Overview.Respir Care. 2020 Feb;65(2):233-251. doi: 10.4187/respcare.06697. Epub 2019 Nov 26. Respir Care. 2020. PMID: 31772069 Review.
Cited by
-
Genetic Association of Pulmonary Surfactant Protein Genes, SFTPA1, SFTPA2, SFTPB, SFTPC, and SFTPD With Cystic Fibrosis.Front Immunol. 2018 Oct 2;9:2256. doi: 10.3389/fimmu.2018.02256. eCollection 2018. Front Immunol. 2018. PMID: 30333828 Free PMC article.
-
Propagation and breakup of liquid menisci and aerosol generation in small airways.J Aerosol Med Pulm Drug Deliv. 2009 Dec;22(4):341-53. doi: 10.1089/jamp.2008.0696. J Aerosol Med Pulm Drug Deliv. 2009. PMID: 19580367 Free PMC article.
-
Dornase alfa for cystic fibrosis.Cochrane Database Syst Rev. 2021 Mar 18;3(3):CD001127. doi: 10.1002/14651858.CD001127.pub5. Cochrane Database Syst Rev. 2021. PMID: 33735508 Free PMC article.
-
Surfactant Dysfunction in ARDS and Bronchiolitis is Repaired with Cyclodextrins.Mil Med. 2018 Mar 1;183(suppl_1):207-215. doi: 10.1093/milmed/usx204. Mil Med. 2018. PMID: 29635617 Free PMC article.
-
Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.Cochrane Database Syst Rev. 2024 May 3;5(5):CD009530. doi: 10.1002/14651858.CD009530.pub5. Cochrane Database Syst Rev. 2024. PMID: 38700027 Free PMC article.
References
-
- Enhorning G. Pulmonary surfactant function in alveoli and conducting airways. Can Respir J. 1996;3:21–27.
-
- Griese M. Pulmonary surfactant in health and lung diseases: state of the art. Eur Respir J. 1999;13:1455–1476. - PubMed
-
- Mander A, Langton-Hewer S, Bernhard W, Warner JO, Postle AD. Altered phospholipid composition and aggregate structure of lung surfactant is associated with impaired lung function in young children with respiratory infections. Am J Respir Cell Mol Biol. 2002;27:714–721. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials